RxDoctor Payments Data

Olusoji Afuwape

General Practice · Dallas, TXNPI 1982165155

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Novo Nordisk. That places this record below the midpoint for general practice clinicians in TX, where the typical reported total is $213.

$28in general payments, 2019–2025

Across 1 payment — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$28
$12,316,200in research payments, 2019–2025

Across 97 payments — averaging $126,971 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$8.1M
  • Lexicon Pharmaceuticals, Inc.$1.9M
  • Mirati Therapeutics, Inc.$1.4M
  • Eli Lilly$733K
  • AbbVie$76K
  • Pfizer$55K
  • plus $135K from 4 others

What the payments were for

  • Food & beverage$28100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$28

How this compares

$28 in reported general payments places this provider in the 10th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Other general practice in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →